These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 9767603)
1. Immunological properties of recombinant proteins of the transmission blocking vaccine candidate, Pfs48/45, of the human malaria parasite Plasmodium falciparum produced in Escherichia coli. Milek RL; Roeffen WF; Kocken CH; Jansen J; Kaan AM; Eling WM; Sauerwein RW; Konings RN Parasite Immunol; 1998 Aug; 20(8):377-85. PubMed ID: 9767603 [TBL] [Abstract][Full Text] [Related]
2. Fusion to Tetrahymena thermophila granule lattice protein 1 confers solubility to sexual stage malaria antigens in Escherichia coli. Agrawal A; Bisharyan Y; Papoyan A; Bednenko J; Cardarelli J; Yao M; Clark T; Berkmen M; Ke N; Colussi P Protein Expr Purif; 2019 Jan; 153():7-17. PubMed ID: 30081196 [TBL] [Abstract][Full Text] [Related]
3. Differential ability of specific regions of Plasmodium falciparum sexual-stage antigen, Pfs230, to induce malaria transmission-blocking immunity. Bustamante PJ; Woodruff DC; Oh J; Keister DB; Muratova O; Williamson KC Parasite Immunol; 2000 Aug; 22(8):373-80. PubMed ID: 10972844 [TBL] [Abstract][Full Text] [Related]
4. Expression, Purification and Characterization of GMZ2'.10C, a Complex Disulphide-Bonded Fusion Protein Vaccine Candidate against the Asexual and Sexual Life-Stages of the Malaria-Causing Plasmodium falciparum Parasite. Mistarz UH; Singh SK; Nguyen TTTN; Roeffen W; Yang F; Lissau C; Madsen SM; Vrang A; Tiendrebeogo RW; Kana IH; Sauerwein RW; Theisen M; Rand KD Pharm Res; 2017 Sep; 34(9):1970-1983. PubMed ID: 28646324 [TBL] [Abstract][Full Text] [Related]
5. Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys. Burns JM; Miura K; Sullivan J; Long CA; Barnwell JW Malar J; 2016 Mar; 15():159. PubMed ID: 26975721 [TBL] [Abstract][Full Text] [Related]
6. Improving the malaria transmission-blocking activity of a Plasmodium falciparum 48/45 based vaccine antigen by SpyTag/SpyCatcher mediated virus-like display. Singh SK; Thrane S; Janitzek CM; Nielsen MA; Theander TG; Theisen M; Salanti A; Sander AF Vaccine; 2017 Jun; 35(30):3726-3732. PubMed ID: 28578824 [TBL] [Abstract][Full Text] [Related]
7. Towards clinical development of a Pfs48/45-based transmission blocking malaria vaccine. Theisen M; Jore MM; Sauerwein R Expert Rev Vaccines; 2017 Apr; 16(4):329-336. PubMed ID: 28043178 [TBL] [Abstract][Full Text] [Related]
9. Immunogenicity of a recombinant malaria vaccine candidate, domain I+II of AMA-1 ectodomain, from Indian P. falciparum alleles. Lalitha PV; Biswas S; Pillai CR; Saxena RK Vaccine; 2008 Aug; 26(35):4526-35. PubMed ID: 18590786 [TBL] [Abstract][Full Text] [Related]
10. A novel plant-produced Pfs25 fusion subunit vaccine induces long-lasting transmission blocking antibody responses. Jones RM; Chichester JA; Manceva S; Gibbs SK; Musiychuk K; Shamloul M; Norikane J; Streatfield SJ; van de Vegte-Bolmer M; Roeffen W; Sauerwein RW; Yusibov V Hum Vaccin Immunother; 2015; 11(1):124-32. PubMed ID: 25483525 [TBL] [Abstract][Full Text] [Related]
11. Prevalence of Plasmodium falciparum transmission reducing immunity among primary school children in a malaria moderate transmission region in Zimbabwe. Paul NH; Vengesai A; Mduluza T; Chipeta J; Midzi N; Bansal GP; Kumar N Acta Trop; 2016 Nov; 163():103-8. PubMed ID: 27491342 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of a Plasmodium-Specific Carrier Protein To Enhance Production of Recombinant Parzych EM; Miura K; Ramanathan A; Long CA; Burns JM Infect Immun; 2018 Jan; 86(1):. PubMed ID: 28993460 [TBL] [Abstract][Full Text] [Related]
14. Nasal immunization with a malaria transmission-blocking vaccine candidate, Pfs25, induces complete protective immunity in mice against field isolates of Plasmodium falciparum. Arakawa T; Komesu A; Otsuki H; Sattabongkot J; Udomsangpetch R; Matsumoto Y; Tsuji N; Wu Y; Torii M; Tsuboi T Infect Immun; 2005 Nov; 73(11):7375-80. PubMed ID: 16239536 [TBL] [Abstract][Full Text] [Related]
15. A C-terminal Pfs48/45 malaria transmission-blocking vaccine candidate produced in the baculovirus expression system. Lee SM; Hickey JM; Miura K; Joshi SB; Volkin DB; King CR; Plieskatt JL Sci Rep; 2020 Jan; 10(1):395. PubMed ID: 31942034 [TBL] [Abstract][Full Text] [Related]
16. Antibody responses to two new Lactococcus lactis-produced recombinant Pfs48/45 and Pfs230 proteins increase with age in malaria patients living in the Central Region of Ghana. Acquah FK; Obboh EK; Asare K; Boampong JN; Nuvor SV; Singh SK; Theisen M; Williamson KC; Amoah LE Malar J; 2017 Aug; 16(1):306. PubMed ID: 28764709 [TBL] [Abstract][Full Text] [Related]
17. A potent malaria transmission blocking vaccine based on codon harmonized full length Pfs48/45 expressed in Escherichia coli. Chowdhury DR; Angov E; Kariuki T; Kumar N PLoS One; 2009 Jul; 4(7):e6352. PubMed ID: 19623257 [TBL] [Abstract][Full Text] [Related]
18. Singh SK; Thrane S; Chourasia BK; Teelen K; Graumans W; Stoter R; van Gemert GJ; van de Vegte-Bolmer MG; Nielsen MA; Salanti A; Sander AF; Sauerwein RW; Jore MM; Theisen M Front Immunol; 2019; 10():1256. PubMed ID: 31231386 [TBL] [Abstract][Full Text] [Related]
19. Antigenicity of a Bacterially Expressed Triple Chimeric Antigen of Plasmodium falciparum AARP, MSP-311 and MSP-119: PfAMSP-Fu35. Kalra A; Edula JR; Gupta PK; Pandey AK; Chauhan VS PLoS One; 2016; 11(10):e0165720. PubMed ID: 27798691 [TBL] [Abstract][Full Text] [Related]